Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis
NCT ID: NCT03243864
Last Updated: 2019-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10 participants
OBSERVATIONAL
2017-03-13
2020-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF
NCT04358991
Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)
NCT00663403
Pharmacokinetics of Antibiotics in Patients Undergoing Renal Replacement Therapies
NCT03636464
Pharmacokinetics of Antibiotics in Critically Ill Patients Receiving CVVHF
NCT04800952
Daptomycin Pharmacokinetics in Continuous Veno-venous Hemodiafiltration
NCT01171547
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ceftazidime and Avibactam
Ceftazidime-avibactam pharmacokinetic monitoring
Ceftazidime-avibactam
Patients will be started on 2.5 gm IV every 8 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ceftazidime-avibactam
Patients will be started on 2.5 gm IV every 8 hours
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients requiring continuous renal replacement therapy (CRRT) due to acute or chronic renal failure
* documented or suspected infection requiring a prescription for ceftazidime-avibactam
Exclusion Criteria
* Patients on ceftazidime-avibactam \< 24 hours
* Patients unable to remain on CRRT for 32 hours continuously without clotting
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Temple University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christina Rose, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
Temple University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Temple University Hospital
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
866
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.